Anagenics Limited

As of June 30, 2025, Anagenics Limited carries a market capitalization of 2.48M, placing it among publicly traded companies globally. Its enterprise value stands at 2.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Anagenics Limited's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2025, Anagenics Limited has 496.32M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 0.49, and the price-to-book ratio stands at 1.36.

These figures are as of June 30, 2025. The EV/Sales ratio of 0.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.93M versus a market cap of 2.48M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Anagenics Limited maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.43, indicating elevated leverage, while an interest coverage ratio of -27.63 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Anagenics Limited posted a negative return on equity (ROE) of -54.48, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.58, reflecting losses generated across the asset base. Inventory turnover of 1.38 indicates how many times Anagenics Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 20, 2026, Anagenics Limited's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2025, Anagenics Limited generated 4.75M in revenue and converted that into -1.24M in net income, yielding earnings per share of 0.00. EBITDA reached -1.12M, while operating income came in at -1.32M.

As of June 30, 2025, Anagenics Limited holds 395,519.00 in cash and equivalents against 848,052.00 in total debt, resulting in a net debt position of 145,697.00. Total book value stands at 1.83M, with working capital of -250,874.00 providing operational flexibility.

Over the twelve months ended June 30, 2025, Anagenics Limited posted a gross margin of 42.92, reflecting its pricing power and cost economics. The operating margin of -27.80 and net profit margin of -26.04 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -13.92, meaning Anagenics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Anagenics Limited's most recent stock split took place on February 21, 2023 with a 741:748 split ratio.

As of June 30, 2025, Anagenics Limited has an Altman Z-Score of -41.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.